[ad_1]
Severe Kovid-19 patients are being treated at the Chicago Hospital in the United States with the antiviral drug Remedaciv from Gilead Sciences. Intensive clinical trials have shown that patients recover more quickly from fever and shortness of breath, and all patients are discharged in less than a week. The United States health website Stat News reported.
Remedacivir was one of the first drugs identified in the laboratory that is likely to affect the new SARS-Cov-2 coronavirus responsible for the creation of Covid-19. Everyone is watching the results of clinical trials at Gilead. If it shows a positive result, it will soon be approved by the US Food and Drug Administration. USA And other regulatory bodies. If it is safe and effective, it will be the first approved treatment for coronavirus.
CNN reports, citing the American health website Stat News, that there has been a significant improvement in Covid-19 patients after the use of the experimental drug remedicivir. All the patients who participated in the clinical trials had high fever and respiratory problems. After applying the medication, all but two recovered and went home in a week. The University of Chicago Medicine conducted a two-stage clinical trial of Gilead with 125 people with symptoms of Covid-19. Of the people who participated in the test, 113 were in critical condition. Daily remedies are given.
Infectious Diseases Specialist from the University of Chicago. Kathleen Mullen leads the clinical trial of the drug. In a related video message, Mullen said, “The good news is that most of our patients have gone home with authorization, which is really cool.” Only two of the participating patients died.
To date, no other clinical data from Gilead’s research has been released, and there is a lot of excitement, reports Stat News. Last month, the President of the United States, Donald Trump, spoke of the possibility of a remediation. “It seems like a very good result,” he said of RemedicV.
“What we can say at this stage is that we await the findings of the ongoing investigation,” Gilead said in a statement Thursday.
The University of Chicago described Mullen’s comments in a video message as “partial information.” A statement from the university said: “Any partial information about the clinical trial is considered incomplete. No such information can be considered conclusive about the possible medical procedures under study.
Gilead previously said he expected results of his test in April. Investigator Mullen said the investigation data would be “locked” to Gilead on Thursday. This means that the results can be known any day.
Mullen has now voiced his doubts to make a final decision. “It is very difficult,” he said. Because, the placebo group drug tests were not compared to drug tests in critically ill patients. However, when we begin to administer medications, the fever graph begins to decrease. The patient can be removed from the ventilator within one day after the start of therapy. So most of all, patients are doing well. ‘
“Most of our patients were in critical condition and most of them were discharged within six days,” said Mullen. This suggests that the duration of therapy will not be 10 days. In very rare cases, the therapy took more than 10 days. That number is only 3. ”
Mullen also confirmed the information to State News. However, he declined to comment in detail.
In a statement, the University of Medicine at Chicago said: “It would be wrong to reach a conclusion at this time and it is not scientifically sound.”
“It is encouraging,” said Eric Tople, director of the Scripps Research Translational Institute. Severe patients have an increased risk of death. If 113 patients are discharged in this case, it is a positive indication of the effectiveness of the drug. However, the data from more research needs to be analyzed.
In this test, two treatment methods were sought for 5 days and 10 days with remedy. Their main objective was to make a statistical comparison of patient improvement between the two medical approaches. Improvement was measured on a seven-point scale, with the worst point on the scale being death and the best result being discharge from the hospital. Furthermore, the issue of oxygen supply at different stages was also on the scale. However, the lack of a control system in this study may be challenging to explain the results.
Previously, two tests in China had to be partially stopped because no patient was found at the time. A recent report says that critically ill patients were given medications under a special program that caused excitement and suspicion.
By scientific definition, all information is anecdotal or unpredictable until full test results are obtained. In other words, a final conclusion cannot be drawn from this information. But some anecdotes are again dramatic.
So far, scientists have found no definitive medication for the treatment of Covid-19. However, the investigation is in full swing. The success of the experimental application of remedicivir is also in its infancy. The drug is being tested in 2,400 severely symptomatic patients in 152 locations around the world. Additionally, the drug is being tested in 1,700 patients with moderate symptoms in 189 hospitals around the world. Gilliad Sciences, the creator of the test, hopes to get the results by the end of this month.
Remedivis, a medication developed by Gilead Sciences, has had some success in treating Ebola before. However, the coronavirus, which is the cause of Covid-19 disease, has shown good success in preventing and treating the virus. Scientists have had significant success, especially in applying the drug to other animals. Last February, the World Health Organization (WHO) also mentioned Remedacivir as a potential medicine for the treatment of Covid-19.
Slaomi Mikalak, a 56-year-old factory worker, participated in the Chicago study. Her daughter developed mild symptoms of Covid-19 in late March. He was treated. Then Mikalak fever started. Acute shortness of breath and back pain increase.
Mikalak told Stat that at that moment it seemed that someone was hitting his lungs. At the urging of his wife, he went to the Chicago Medical Hospital. On April 3, his fever rose to 104 degrees and his breathing worsened. They gave him oxygen in the hospital. He agreed to participate in a clinical trial in Gilead. On April 4, he received remediation. Almost immediately her fever decreased and she began to feel better than before. The next day they gave him a second dose of medicine and he no longer needed oxygen. Then they gave him remediation twice more. On April 6, he was released from the hospital.
“It is a miracle drug,” said Mikalak. “It just caught our eye then.
[ad_2]
